SOFAST Study:

SOFIA Aspiration System as first-line Technique
SOFIA™ Aspiration Catheter

"First-line aspiration with SOFIA 6F is safe and effective with high revascularization rates and short procedure times."

Patients

108

Country

US

Clinical Centers

12

Design

Single arm prospective

Scope

Patients 21-85 y.o. presenting with an acute ischemic stroke from imaging-confrimed LVO in the anterior cerebral circulation within 90min from arteriotomy, Aspect ≥ 6 and NIHSS ≥ 5, within 8 hrs of symptom onset or last known well. Those eligible to be treated with SOFIA™ Flow Plus 6F as 1st line treatment.

Purpose

To assess safety and efficacy of SOFIA Flow Plus 6F used for first-line aspiration in anterior circulation LVO stroke patients.

Endpoints

Proportion of patients with vascular recanalization defined as mTICI≥2b at the end of the procedure per Core Lab evaluation

Efficacy results

At the end of procedure:

  • mTICI≥2b= 97.2%

  • mTICI≥2c= 85.2%

  • mTICI 3=55.6%

With SOFIA 6F 1st line aspiration:

  • mTICI≥2b= 87.0%

  • mTICI≥2c= 79.6%

  • mTICI 3= 52.8%

  • FPE (TICI3)= 50.9%

  • FPE (mTICI≥2b)= 75.0%

Median times:

  • From arteriotomy to clot contact: 12 min

  • From arteriotomy to mTICI≥2b: 17 min

Safety results

  • Symptomatic within 24 hours = 0.9%

  • Vessel perforation = 0.9%

  • ENTs = 0%

At 3 months:

  • all cause mortality = 7.4%

At 3 months:

  • mRS 0-2 = 66.7%


Please refer to Instruction for Use (IFU) in the specific market/country that you are looking into:

Explore more studies

STABILISE Study: Stroke: an evaluation of thrombectomy in the ageing brain version 1

SOFIA™ Aspiration Catheter & ERIC™ Stent Retriever

SESAME Study: Safety and Effectiveness of SOFIA™/​SOFIA™ PLUS for Direct Aspiration in Acute Ischemic Stroke

SOFIA™ Aspiration Catheter

HEAT Study: Hydrogel Endovascular Aneurysm Treatment Trial

Hydrogel Embolic Coils

Request more information

The information you provide through this form is necessary to respond to your request and may be shared with the relevant Terumo Neuro group entity or entities responsible for handling it. For more information on how we process your personal data and on your rights, please refer to our privacy policy.